News Results for Dechra Pharmaceuticals (DPH)

Pharmaceuticals company Dechra Pharmaceuticals reported a rise in revenue led by 'good' market penetration of its core portfolio. For the financial year ended 30 June 2020, revenue increased by...

JP Morgan Cazenove today reaffirms its overweight investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and cut its price target to 3200p (from 3300p). Story provided by StockMarketWire.com...

An afternoon rally fizzled out as the FTSE 100 closed well into the red on Thursday, weighed down by negative macroeconomic news with total unemployment claims in the US now worse than expected....

RBC Capital Markets today reaffirms its sector performer investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and cut its price target to 2510p (from 2560p). Story provided by...

The FTSE 100 dropped lower on Thursday, weighed down by oil shares after a big fall in brent crude prices heightened concerns over a large build-up of US inventories. At 1200, the UK's benchmark...

Pharmaceutical company Dechra Pharmaceuticals said it had raised gross proceeds of £133.4m through the placing of shares at a discount. A total of 5,132,500 were placed at price of 2,600p,...

HSBC today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 3085p (from 3020p). Story provided by StockMarketWire.com Broker Forecasts...

Dechra said it had completed the acquisition of the worldwide rights of Kindred Biosciences' cat weight loss treatment portfolio for $43m. The addition of Mirataz 'significantly enhances the...

Dechra Pharmaceuticals said it had agreed terms to acquire the global rights to the cat weight loss treatment portfolio from Kindred Biosciences for $43m and a royalty on future sales. Mirataz...

RBC Capital Markets today reaffirms its sector performer investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2530p (from 2500p). Story provided by...

JP Morgan Cazenove today reaffirms its overweight investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 3300p (from 3200p). Story provided by...

UK stocks slumped on Monday as investors scurried to safer assets including gold following a sharp rise in coronavirus cases outside China, which stoked fears over a possible pandemic that would...

UK stocks slumped on Monday after the spread of coronavirus in countries outside of China, including South Korea and Italy, stoked global pandemic fears. By 11.29 a.m. the benchmark FTSE 100 index...

UK stocks opened substantially lower on Monday after the spread of coronovirus in countries outside of China, including South Korea and Italy, stoked global pandemic fears. At 0818, the benchmark...

Veterinary pharmaceuticals company Dechra Pharm said half-yearly profit more than doubled, led by 'strong' revenue in its European business, though it warned of supply challenges in North America....

Jefferies International today downgrades its investment rating on Dechra Pharmaceuticals PLC (LON:DPH) to hold (from buy) and cut its price target to 2930p (from 3090p). Story provided by...

Dechra Pharmaceuticals said that annual performance would be weighted more to the second half of the year than was typical for the company. Outlook for the full year was in line with management...

UK markets ended the Monday trading session firmly in the red on Monday as escalating political tensions between the US and Iran led investors to strap on their tin hats as oil and gold prices...

JP Morgan Cazenove today reaffirms its overweight investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and cut its price target to 3200p (from 3500p). Story provided by StockMarketWire.com...

Dechra said it had agreed terms to acquire the global rights to the Osurnia product portfolio from Elanco Animal Health for $135m. The addition of Osurnia - a long acting treatment for otitis...

HSBC today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2950p (from 2915p). Story provided by StockMarketWire.com Broker Forecasts...

Animal pharmaceuticals supplier Dechra Pharmaceuticals announced that it had appointed acting chief financial officer Paul Sandland to the position permanently. Between 2012 and 2013, Sandland was...

Dechra Pharmaceuticals said it would continue efforts to resolve its supply issues, but added that many of the issues had now been mitigated, leaving it 'confident' about its prospects for the...

Ian Page, Chief Executive Officer, exercised 73,260 shares in the company on the 19th September 2019 at a price of 0.00p. The Director now holds 659,910 shares. Story provided by...

Ian Page, Chief Executive Officer, sold post-exercise 34,536 shares in the company on the 20th September 2019 at a price of 2789.37p. The Director now holds 625,374 shares. NOTE: Sold to meet tax...

Tony Griffin, Executive Director, exercised 20,858 shares in the company on the 19th September 2019 at a price of 0.00p. The Director now holds 91,464 shares. Story provided by...

Ian Page, Chief Executive Officer, sold 200,000 shares in the company on the 17th September 2019 at a price of 2916.95p. The Director now holds 586,650 shares. NOTE: Sold to satisfy long term...

Tony Rice, Chairman, sold 20,000 shares in the company on the 17th September 2019 at a price of 2909.97p. The Director now holds 20,000 shares. NOTE: Sold to satisfy long term personal financial...

JP Morgan Cazenove today reaffirms its overweight investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 3500p (from 3000p). Story provided by...

UK stocks held on to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his...

UK stocks added to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his...

UK stocks opened higher on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership...

Dechra Pharmaceutical reported a slight fall in profit even as the animal-drug developer outperformed in all its markets including in the US where it delivered 'exceptional' organic growth....

Dechra said it had acquired Ampharmco for $30m in cash. Ampharmco (APC), founded in 1999 as a veterinary contract manufacturer, specialised in companion animal products and subsequently received...

Dechra said it had signed a licensing and supply agreement with Akston Biosciences Corporation for the rights to the latter's drug to treat diabetes in dogs for a total payment of up to $14m....

At midday the FTSE 100 was up a handful points, recovering from earlier losses, amid continuing Brexit-related pressure on sterling. Industrial group Melrose fell 7.2% following negative news from...

Animal-drug developer Dechra Pharmaceutical said revenues increased by about 17% amid another year of 'strong growth' driven by 'good' market penetration and the realisation of significant...

Dechra acquired a further 15% stake in Medical Ethics for a total of about AUD$13.5m from the current shareholders, taking its total holdings in the company to 48%. Dechra's said its investment...

As the S&P 500 advanced 0.6% in the US, the FTSE 100 closed up 0.4% at 7,418.28 with gains constrained by sterling strength amid cross-party efforts to prevent a no-deal Brexit. Elsewhere...

Sterling bounced back from a weaker performance after Theresa May said she was willing to hold Brexit talks with Jeremy Corbyn and request a short extension from the European Union. At around 9am,...

Dechra said Richard Cotton, Chief Financial Officer, would leave the company immediately for 'personal reasons'. 'The Board has agreed that with immediate effect Richard will resign as Director...

Jefferies International today reaffirms its buy investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2805p (from 2466p). Story provided by StockMarketWire.com...

JP Morgan Cazenove today initiates coverage of Dechra Pharmaceuticals PLC (LON:DPH) with a overweight investment rating and price target of 3000p. Story provided by StockMarketWire.com Broker...

HSBC today reaffirms its buy investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and cut its price target to 2700p (from 2770p). Story provided by StockMarketWire.com Broker Forecasts data...

Dechra Pharmaceuticals, which develops drugs for animals, reported Monday first-half results that met its expectations, led by strong growth in its North American division. For the six months...

HSBC today initiates coverage of Dechra Pharmaceuticals PLC (LON:DPH) with a buy investment rating and price target of 2770p. Story provided by StockMarketWire.com Broker Forecasts data provided...

The FTSE 100 clawed back some losses but remained in the red, down 0.9% at 6,855, after downbeat Chinese data concerned investors. Reports of progress between the US and China on a potential...

The FTSE 100 is down more than 1% to 6,844.84 by Monday lunchtime as investors react to figures overnight in China showing a deterioration in both imports and exports. US futures are also pointing...

Dechra Pharmaceuticals, which supplies drugs for animals, said trading in the first half of the year was in line with its expectations amid double-digit percentage growth in both its European and...

Tony Griffin, Executive Director, sold 5,000 shares in the company on the 18th December 2018 at a price of 2115.37p. The Director now holds 70,606 shares. Story provided by StockMarketWire.com...

Dechra Pharmaceuticals on Tuesday completed the acquisition of the Brazilian-based Venco. Venco had a large portfolio of vaccines and other food producing animal products, which it sold...

RBC Capital Markets today reaffirms its sector performer investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and cut its price target to 2100p (from 2400p). Story provided by...

Ian Page, Chief Executive Officer, exercised 90,721 shares in the company on the 22nd October 2018 at a price of 0.00p. The Director now holds 829,418 shares. Story provided by...

Ian Page, Chief Executive Officer, sold post-exercise 42,768 shares in the company on the 22nd October 2018 at a price of 2139.60p. The Director now holds 786,650 shares. Story provided by...

Tony Griffin, Executive Director, exercised 22,641 shares in the company on the 22nd October 2018 at a price of 0.00p. The Director now holds 86,961 shares. Story provided by StockMarketWire.com...

Tony Griffin, Executive Director, sold post-exercise 11,355 shares in the company on the 22nd October 2018 at a price of 2139.60p. The Director now holds 75,606 shares. Story provided by...

Richard Cotton, Director, exercised 21,033 shares in the company on the 22nd October 2018 at a price of 0.00p. The Director now holds 63,384 shares. Story provided by StockMarketWire.com...

UK stocks opened higher on Friday after the Chinese market was buoyed by pledges of government support and the UK and EU appeared to be moving closer to finalising a Brexit deal. Chinese economic...

Dechra Pharmaceuticals said it was 'confident' in delivering on full-year guidance after fiscal first-quarter performance was in line with management's expectations, led by growth in both EU and...

Dechra Pharmaceuticals said Monday it had acquire Caledonian Holdings for NZD 8.7m, or about £4.4m. Caledonian was established in 2010 by a group of entrepreneurial equine veterinarians in New...

Disappointing manufacturing data and concerns over Brexit kept the pound under pressure, boosting the FTSE 100. The index closed 1% higher at 7,504 thanks to gains in oil and mining stocks. Oil...

The FTSE 100 took advantage as the pound fell on the revelation that EU chief negotiator Michel Barnier was opposed to UK prime minister Theresa May's trade proposals leading to renewed warnings...

Numis today downgrades its investment rating on Dechra Pharmaceuticals PLC (LON:DPH) to hold (from add). Story provided by StockMarketWire.com Broker Forecasts data provided by...

UK stocks opened higher on Monday after the EU's chief Brexit negotiator Michael Barnier said he was 'strongly opposed' to the UK's trade plans, triggering a fall in the pound that helped...

Veterinary medicine supplier Dechra Pharmaceuticals reported Monday a modest improvement in annual profit as rising revenue was offset by one-off costs associated with acquisitions. For the year...

Numis today reaffirms its add investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2950p (from 2640p). Story provided by StockMarketWire.com Broker Forecasts...

Dechra Pharmaceuticals said Tuesday trading in the year through June had been 'strong' and in line with management expectations. For the 12 months to 30 June, reported group revenue is expected...

Ian Page, Chief Executive Officer, exercised 1,465 shares in the company on the 2nd March 2018 at a price of 614.00p. The Director now holds 738,697 shares. Story provided by StockMarketWire.com...

Richard Cotton, Director, exercised 21,033 shares in the company on the 26th February 2018 at a price of 0.00p. The Director now holds 42,351 shares. Story provided by StockMarketWire.com...

There was a strong start to the new trading week for markets in Asia, Europe and the US. China's governing Communist Party has proposed to let Xi Jinping extend his presidency beyond 2023, thereby...

Asian equities performed strongly on Monday, setting a positive tone for other markets around the world. The FTSE 100 traded 0.4% higher at 7,277, helping by gains in mining stocks. A 0.8% rise...

Dechra Pharmaceuticals reported revenue of £194.1m for the six months ended 31 December 2017, up 11.2% at constant exchange rate (CER) 12.5% on actual exchange rate (AER). The firm declared an...

Numis today reaffirms its add investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and set its price target at 2640p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Jefferies International today upgrades its investment rating on Dechra Pharmaceuticals PLC (LON:DPH) to buy (from hold) and raised its price target to 2631p (from 2221p). Story provided by...

Jefferies International today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and set its price target at 2221p. Story provided by StockMarketWire.com

A rally in UK grocers kept the FTSE travelling higher thanks to encouraging Christmas trading from Morrisons (MRW). Morrisons was up 2.4% at 232.3p following a 2.8% jump in like-for-like sales...

Supermarkets rallied on the back of Morrison's strong Christmas trading, helping to push the FTSE 100 0.3% higher to 7,724 around midday. Morrisons (MRW) reported a 2.8% jump in like-for-like...

Dechra Pharmaceuticals said trading in the period from the start of July to the end of December was strong and in line with management expectations. Reported group revenue increased by around...

Dechra Pharmaceuticals' performance in the first quarter was in line with management expectations, with continued growth across all of its markets, shareholders at today's annual general meeting...

Ian Page, Chief Executive Officer, sold post-exercise 54,910 shares in the company on the 19th September 2017 at a price of 2023.91p. The Director now holds 737,232 shares. NOTE: Sold to meet tax...

Tony Griffin, Executive Director, sold post-exercise 29,937 shares in the company on the 19th September 2017 at a price of 2023.91p. The Director now holds 64,320 shares. NOTE: Sold to meet tax...

Tony Griffin, Executive Director, exercised 29,937 shares in the company on the 19th September 2017 at a price of 0.00p. The Director now holds 94,257 shares. Story provided by...

Ian Page, Chief Executive Officer, exercised 115,334 shares in the company on the 19th September 2017 at a price of 0.00p. The Director now holds 792,142 shares. Story provided by...

Cantor Fitzgerald today reaffirms its buy investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2200p (from 1500p). Story provided by StockMarketWire.com

Jefferies International today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 1868p (from 1565p). Story provided by StockMarketWire.com

Richard Cotton, Director, bought 8,481 shares in the company on the 4th September 2017 at a price of 1974.63p. The Director now holds 21,318 shares. Story provided by StockMarketWire.com...

Dechra Pharmaceuticals said trading in the year ended 30 June was strong and in line with management expectations, with a good performance from the core business complemented by the successful...

Story provided by StockMarketWire.com

Ian Page, Chief Executive Officer, sold 134,500 shares in the company on the 21st June 2017 at a price of 1927.00p. The Director now holds 676,808 shares. Story provided by StockMarketWire.com...

Ian Page, Chief Executive Officer, has transferred out 6,600 shares in the company on the 24th April 2017 at a price of 0.00p. The Director now holds 811,308 shares. NOTE: Shares no longer a...

Numis today reaffirms its add investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 1890p (from 1700p). Story provided by StockMarketWire.com

Stifel today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 1550p (from 1440p). Story provided by StockMarketWire.com

Tony Griffin, Executive Director, sold 3,500 shares in the company on the 21st March 2017 at a price of 1676.00p. The Director now holds 64,320 shares. Story provided by StockMarketWire.com...

RBC Capital Markets today reaffirms its outperform investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 1890p (from 1630p). Story provided by StockMarketWire.com

Jefferies International today reaffirms its hold investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 1565p (from 1320p). Story provided by StockMarketWire.com

Numis today reaffirms its add investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and set its price target at 1700p. Story provided by StockMarketWire.com

Dechra Pharmaceuticals posts underlying operating profits of £38.6m for the six months to the end of December - up 47.1% at actual exchange rates and 28.6% at constant currencies. Revenues of...

Story provided by StockMarketWire.com

Dechra Pharmaceuticals says reported group revenue for the six months to the end of December increased by approximately 34% at constant exchange rate (56% at actual exchange rate). Core group...